XtalPi Collaborated with Eli Lilly on AI Drug Discovery for ~$250M
Shots:
- XtalPi will receive ~$250M up front and milestones. The collaboration focuses on using AI and robotics in drug discovery
- The collaboration will use XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi brings together AI “dry lab” algorithms and “wet lab” robotics to drive innovation
- The collaboration will leverage the AI drug discovery solution to create a novel compound which will be advanced by Lilly through clinical and commercial development. XtalPi’s ID4Inno small-molecule drug discovery platform helps to create and explore a target-specific mega-chemical space as well as identify a promising lead series
Ref: PRNewswire | Image: XtalPi
Related News:- XtalPi Collaborated with CK Life Sciences to Develop AI-Empowered Tumour Vaccine Research and Development Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
